IP Library Granted Patent US 6,887,860
Granted Patent B2
US 6,887,860 · App. 10/462,272 · Granted May 3, 2005

(20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,887,860
App. No.
10/462,272
Granted
May 3, 2005
Kind
B2
Abstract

This invention discloses (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat immune disorders in humans as well as renal osteodystrophy.

Claims (6)

1. A method of treating psoriasis comprising administering to a patient with psoriasis an effective amount of (20S)-1α-hydroxy-2-methylene -19-nor-bishomopregnacalciferol having the formula:

2. The method of claim 1 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.

3. The method of claim 1 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.

4. The method of claim 1 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.

5. The method of claim 1 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered topically.

6. The method of claim 1 wherein (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μg/day to about 100 μg/day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2012
From: DELUCA, HECTOR F.; PLUM, LORI A.; CLAGETT-DAME, MARGARET
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 029231/0807 →
SECURITY AGREEMENT Recorded Apr 24, 2009
From: QUATRX PHARMACEUTICALS COMPANY
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 022584/0669 →